ENGLISH ABSTRACT
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

[Pharmacovigilance update].

Revue Médicale Suisse 2019 January 10
The main pharmacovigilance updates in 2018 are reviewed. Quinolones : no longer recommended for mild or moderately severe infections. Denosumab in cancer patients: increased risk of new primary malignancies. Cyproterone : increased risk of meningioma at high dose. Saccharomyces boulardii : risk of fungemia in frail patients. Ulipristal : risk of hepatotoxicity. Daclizumab : early withdrawal from the market as risks clearly outweigh benefits. Interactions between boosted antiretrovirals and anti-P2Y12 : prasugrel appears as the best option. Neural tube defects in babies born to women treated with dolutegravir : a signal to investigate. Cobicistat-boosted antiretrovirals exposure is decreased during pregnancy. Fourth generation pills containing drospirenone : a greater propensity to prolong the QT interval than 2nd generation pills.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app